Ovarian Cancer Recurrent
Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
3 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
ADC
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
DS
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
2029
2030
InxMedIN10018
Daiichi SankyoRaludotatug Deruxtecan
Outpace BioOPB-101
Clinical Trials (3)
Total enrollment: 448 patients across 3 trials
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Start: Sep 2022Est. completion: Dec 2026168 patients
Phase 2Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Start: Apr 2025Est. completion: Mar 2029280 patients
Phase 1/2Recruiting
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Start: Jun 2025Est. completion: May 2030
Phase 1Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
1h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
1h ago
Office Administrator
SystImmune
1h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
1h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
1h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
1h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 actively recruiting trials targeting 448 patients
3 companies competing in this space